Red Light Holland (TRIP) is purchasing 100 acres of farmland for $1.85M to expand its mushroom cultivation operations. 65,000 square feet of production facilities will be built this summer.
Both the Senate and the House of Delegates approved a Maryland bill that would provide veterans with free psilocybin, MDMA, and ketamine treatments for PTSD or traumatic brain injury.
If approved by the governor, the state would devote $1M per year to funding the treatments.
| A recent survey of 200,000+ people found that those who have used psilocybin at least once are 30% less likely to have opioid use disorder. However, LSD, mescaline, and peyote use did not seem to have an impact on opioid use. Addiction is linked with abnormal serotonin neurotransmission. Since psilocybin targets the serotonin system, it may help protect against opioid addiction. Learn more with Chloe Deutscher on TikTok |
Manufacturing Contract with the Toronto Institute of Pharmaceutical Technology
Vancouver, British Columbia – April 07, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has consummated a contract with the Toronto Institute of Pharmaceutical Technology (TIPT®) to formulate and manufacture psilocybin microdose capsules for its upcoming Canadian Phase 2A fragile X syndrome (“FXS”) clinical study.
“Autism spectrum disorder (“ASD”) and especially FXS, the largest genetic cause of ASD, continue to have unmet medical needs. Scientists at NOVA, over the past two years, have laid the groundwork for development of potential novel psilocybin-based microdose treatment of ASD,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “The recently completed preclinical study of repeat low doses of our psilocybin drug – every other day for 2 weeks, showed clinical responses that greatly exceeded our expectations. We significantly modulated behavioural and cognitive defects, such as recognition memory, in FXS.”
NOVA plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS.
NOVA is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of FXS. Furthermore, NOVA has manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization following drug approval.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca.
About TIPT
The Toronto Institute of Pharmaceutical Technology (TIPT®) is North America’s premier pharmaceutical institute of education, technology and research. We operate a fully compliant Health Canada-licensed GMP manufacturing and testing facility for solid dosage forms and liquid preparations.
Since our inception in 1992, we have successfully established corporate partnerships with leading pharmaceutical companies worldwide and have provided innovative product development solutions uniquely supported by pragmatic institutional experts.
For more information, please visit: www.tipt.com.
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.
We’d love to hear what PETA thinks of this idea…
Alistair McTaggart, a University of Queensland researcher, discovered what he believes is a new species of psychedelic mushroom in one of Australia’s biggest national parks.
When interviewed on the finding, he brought attention to an “under-explored” use of psilocybin: animal welfare.
“Psilocybin has use in [treating] anxiety in humans, we don’t understand the effects of psilocybin on animals very well, but I think of slaughterhouses and what this could mean for the meat [processing] industry,” McTaggart explains.
Who knows, maybe we’ll start seeing beef advertised as “shroom-fed” 🤷♀️
MARCH 30th 2022 – VANCOUVER, BRITISH COLUMBIA
Albert Labs International Corp. (CSE: ABRT), (FSE: VB50) (the “Company”), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs’ culturing process can significantly increase the production volumes of psilocybin medicine. The Company sees the demand for naturally produced psilocybin continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide.
The improved quality and consistency enabled by this patent-pending process are paramount to scaling the Eu-GMP production of psilocybin Active Pharmaceutical Ingredient (API). The new process and methodology optimized key parameters necessary for the efficient cultivation that results in an increased high-quality yield of Psilocybe mycelia. The same patent-pending process and methodology can also be applied to the optimized cultivation of other fungi species, opening up the untapped potential market of bio-active fungal compounds. This is not a synthetic or biosynthetic process and does not use or introduce harmful synthetic chemicals or genetically modified bacteria in the production of psilocybin. Batch to batch, Albert Labs’ bioreactor design allows them to produce strong yields of consistent psilocybin API, which will continue to be assessed for clinical efficacy and safety through Albert Labs’ upcoming real-world evidence trials.
“At Albert Labs, we focus on the science of producing and extracting natural product pharmacologically bioactives for mental health. Today’s announcement is a testament to the R&D and engineering expertise we have on our team. Albert Labs’ manufacturing technology breakthrough represents a very significant step forward in our production capabilities for pharmaceutical-quality psilocybin with consistent and standardized psychoactive properties. API consistency is critically important for regulatory approval, and unfortunately, many “field grown” natural substances are too variable for pharmaceutical usage. While a massive body of science dating back many centuries suggests that natural products can have major medicinal benefits, “crop-to-crop” variability has been a severe drawback for their use in regulated pharmaceuticals for many decades. Using this new Albert Labs’ technology, the consistent quality of our API is a significant step forward to delivering our first trial drug, KRN-101, to patients and thus to treating millions of suffers with unmet mental health needs.” Added Dr Michael Raymont, Chief Executive Officer.
“The newly filed patent-pending process and methodology was painstakingly developed at Albert Labs using rigorous scientific methods. For the first time, scalable production of Psilocybe mycelia using an all-natural process, can be used to address the ever-increasing demand from global markets”, said Parminder Singh, head of Albert Labs’ Scientific Advisory Board.
Business of Albert Labs
A clinical research and drug development enterprise, Albert Labs and its team are experts at producing and extracting natural drug candidates. Albert Labs looks to develop solutions to the mental health epidemic through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized pathway heavily used in the successful development of Covid-19 vaccines. This accelerated development pathway will facilitate Albert Labs in delivering on its goal of receiving market authorization and creating highly successful, licensed medicines.
Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to their treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.
Albert Labs recently executed a listing on the Canadian Securities Exchange (CSE) under the ticker ABRT. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here.
ON BEHALF OF THE BOARD OF DIRECTORS
Albert Labs International Corp.
Dr. Michael Raymont
Chief Executive Officer & Chairman
For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Tel: +1 778-819-0740
Cautionary Statement
This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.
The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities law
TORONTO, March 29, 2022 /CNW/ – Diamond Therapeutics Inc., a drug development company focused on non-psychedelic doses of psilocybin for use in the treatment of mental health, announces the completion of last patient last visit (LPLV) in its Phase 1 clinical trial of low doses of psilocybin. LPLV is the date upon which the last subject completes a clinical study. The study’s final patient follow-up visit was March 12, 2022.
This randomized, double-blind trial is the first systematic, placebo-controlled, single ascending dose study to investigate very low doses of psilocybin in humans. The study assesses psilocybin’s safety and tolerability. The aim is to identify an active, non-psychedelic dosage.
For the trial, fifty-six persons were enrolled in seven separate cohorts over four and a half months. A panel of five senior, highly experienced physicians reviewed all safety data as it became available.
“Before this study, little proper, controlled research had been done to investigate very low concentrations of psilocybin,” says Dr. Michael B. McDonnell, Chief Medical Officer of Diamond. “Diamond’s study is robust and well designed with controls for bias and expectancy. It will advance our understanding of the therapeutic potential of very low doses of psilocybin.”
The trial was conducted in Toronto under the supervision of principal investigator Dr. Isabella Szeto of BioPharma Services Inc., the contract research organization working with Diamond. Diamond anticipates topline results will be available by May 2022, with a complete analysis to follow.
“We look forward to sharing the study data as soon as all analysis is complete,” says Judy Blumstock, Diamond’s founder and CEO. “The results from this landmark trial will catalyze our planned phase two studies. We are closer to achieving our goal of bringing new and better accessible alternative therapeutics to the millions of people struggling with mental health disorders. “
About Diamond Therapeutics
Diamond Therapeutics is a drug development company based in Toronto, Ontario. Our mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. Diamond is focused on sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort —maximizing the positive impact better drugs can have on global mental health. To learn more about Diamond, visit www.diamondthera.com.
Cautionary Statements Regarding Forward-Looking Information
This news release includes certain “forward-looking information” under applicable Canadian securities legislation. Forward-looking information includes statements other than statements of historical fact that can be identified by phrases such as “expects”, “anticipates”, “intends”, “aims”, “plans” and “believes”, and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements in this news release include, but are not limited to, the potential effects of low dose psilocybin and other psychedelic treatments, the potential use in treating mental health conditions and the timing and completion of Diamond’s clinical programs and trials. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive applicable regulatory approvals; that factors may occur which impede Diamond’s future business plans; the results of continued development, marketing and sales; and other factors beyond the control of Diamond. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Diamond disclaims any intention or obligation to update or revise any forward-looking information in this news release, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/diamond-therapeutics-achieves-last-patient-last-visit-in-clinical-trial-of-low-dose-psilocybin-301512890.html
SOURCE Diamond Therapeutics Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2022/29/c5990.html
— IND-enabling safety pharmacology and toxicology studies completed in multiple species under GLP guidelines –
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, is pleased to report the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (MDD). Data from in vivo preclinical studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. The preclinical in vivo studies followed FDA protocol and were completed under Good Laboratory Practice (“GLP”) guidelines.
“The completion of these in vivo preclinical studies for CYB003 represents a significant milestone toward advancing this program into first-in-human clinical development and brings us one step closer to progressing CYB003 as a best-in-class treatment candidate for mental illness and addiction. We plan to focus the Phase 1/2a trial in the United States. We believe this will allow us to escalate the study through early-stage clinical development and into a potential broader Phase 2b trial, while concurrently collecting a large amount of data to support late-stage studies,” said Doug Drysdale, Chief Executive Officer of Cybin.
“We are excited to complete this integral step toward moving CYB003 into the clinic – an impressive journey that took less than 18 months since discovery of the CYB003 molecule. Based on its attractive preclinical profile and the ability to translate these results in patients, we believe that CYB003 has the potential to be a novel and effective treatment for the many people suffering from MDD,” said Dr. Amir Inamdar, Chief Medical Officer of Cybin.
Preclinical Study Results:
In multi-species preclinical studies, CYB003 demonstrated:
About CYB003
CYB003 is derived from psilocybin, which is part of a family of molecules called indolamines that include more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD).
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the period ended December 31, 2021 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor & Media Contacts:
Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com
Source: Cybin Inc.
VANCOUVER, BC, March 29, 2022 /CNW/ – Nirvana Life Sciences Inc., (“Nirvana” or the “Company”) (CSE: NIRV) is pleased to announce that it has entered a supply agreement with Symeres B.V. for the supply of compounds to support the Company’s ongoing research program. Under this agreement Symeres will supply Psilocybin and other materials to be used in trials and ongoing research.
Dr. Sazzad Hossain, Chief Scientific Officer of Nirvana commented, “We are very pleased to be able to work with a firm with the broad capabilities that Symeres offers as we enter the next phase of research and development.,” “Symeres is one of Europe’s leading Contract Research Organizations (CRO) that has the capacity to produce and supply many of the compounds essential to our research”.About Symeres
Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services and manufacturing to major pharmaceutical and biotechnology companies around the globe. Its highly specialized services include: integrated small molecule optimization efforts, complex synthetic chemistry, route scouting & drug synthesis up to GMP production, solid state chemistry and ADME-Tox services.About Nirvana Life Sciences
Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelics space. Its business model combines the development of novel formulations for drug development with the development of laboratory space to support ongoing development and manufacturing. At Nirvana, we believe that psylocibins derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities. For more information visit https://nirvanalifescience.com/
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.Forward-Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
SOURCE Nirvana Life Sciences Inc.
For further information: Bruce Clark CEO, info@nirvanalifescience.com, Phone: 604-401-8100
Highlights:
Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that wholly-owned, Canadian based psychedelics company, Halucenex Life Sciences Inc. (“Halucenex”) has completed several milestones that will allow the Company to progress its first psilocybin mushroom harvest and other product development initiatives.
Upgrades to state-of-the-art grow room:
Halucenex has completed a series of renovations to its grow rooms at its medical facility in Nova Scotia. The recent upgrades will lay the foundation for the Company’s maiden harvest of inoculated psilocybe mushrooms. The Company has completed the installation of food-grade washable wall and ceiling panels, as well as commissioned heat and humidity control systems for growing psilocybe mushrooms. The facility upgrade follows extensive internal consultations and discussions with partners to ensure optimal growing conditions.
Halucenex will now progress steps towards cultivation and anticipates its first harvest to complete within the next three months. Harvested psilocybe mushrooms will then be used for R&D and product development initiatives.
Successfully commissioning of High Performance Liquid Chromatography (HPLC) System:
Halucenex has also recently installed a high performance liquid chromatography system at its medical facility in Nova Scotia, which will be utilised to test the active pharmaceutical ingredients (API) in both synthetic and botanical psilocybe mushrooms.
HPLC is an analytical chemistry technique used to separate, identify and quantify each component in a mixture. The method is commonly used for pharmaceutical manufacturing, R&D and for medical purposes.
Halucenex will use the new HPLC system to gain further insight into the level of APIs in synthetic and botanical psilocybe mushrooms cultivated at its facility. This is an important development, as it will provide Halucenex with additional data which can be used for initial product development initiatives.
Method development for psilocybin and psilocin potency and purity testing are currently being established in collaboration with the Company’s R&D partners.
Commentary:
Managing Director and CEO Mr William Lay said: “Halucenex has continued to make very strong, value accretive progress over the course of 2022.
“The successful commissioning of the HPLC system will allow the group to gain a detailed understanding of botanical and synthetic psilocybin content and purity. This is imperative as we move towards product development and other research initiatives.
“The recent renovations to the Company’s grow room are an important milestone ahead of our first planned harvest. The initiative has laid a strong foundation to commence cultivation, which will provide cost effective biomass for R&D purposes.
“The Board and management look forward to providing additional updates to shareholders, once ethics approval for the planned clinical trial has been secured and patient recruitment initiatives are underway.”
-Ends
